Excluding NICE from early stages of value based pricing scheme was “big win for pharma,” conference is toldBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6906 (Published 18 November 2013) Cite this as: BMJ 2013;347:f6906
- Matthew Limb
- 1 London
The delay to the involvement of the UK National Institute for Health and Care Excellence (NICE) in developing a new system in England for pricing drugs amounted to a “big win for pharma,” an industry expert has said.
Paul Catchpole, director of value and access for the Association of the British Pharmaceutical Industry, made his comments at the European Pharma Regulation 2013 conference in London on 13 November.
Earlier this month the industry body negotiated an extension of the voluntary Pharmaceutical Price Regulation Scheme with the government.1 This means that NHS spending on branded drugs will be held flat for the next two years, with increases of less than 2% in the following three years.
The new system of value …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial